Table 2 Characteristics of treatment exposures included in the meta-analysis

CRUISE (2010)

IVR 0.5 mg (n = 130)

IVR 0.5 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months

IVR 0.3 mg (n = 132)

IVR 0.3 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months

Sham injection (n = 130)

sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months

ROCC (2010)

IVR 0.5 mg (n = 16)

IVR 0.5 mg every month for 3 months, then as required (at the discretion of the physician) for persisting macular oedema

Sham injection (n = 16)

sham injection (plastic syringe pressed against the eyeball)

BRAVO (2011)

IVR 0.5 mg (n = 131)

IVR 0.5 mg monthly injections then PRN (open-label) for 6 months

IVR 0.3 mg (n = 134)

IVR 0.3 mg monthly injections then PRN (open-label) for 6 months

Sham injection (n = 132)

sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months

Tan (2014)

IVR 0.5 mg (n = 15)

IVR 0.5 mg monthly injections up to month 5 then PRN for 6 months

Sham injection plus laser (n = 21)

sham injection monthly up to month 5 then PRN for 6 months, laser at week 13 and 25 if eligible